Dianthus Therapeutics Inc

DNTH is in Stage 3 distribution with price below its 50-day SMA and short EMAs, consistent with the active Bearish Pivot Point pattern signaling structural repair lower. The medium-term bias is bearish, and short-term execution readiness is confirmed by price extension and rejection below the 9/20 EMAs. Executing Sell Now into rallies back toward the 9/20 EMA and 50-day SMA resistance aligns with the prevailing downward momentum and pattern implications.

• ↑DNTH312 bifunctional fusion protein targets complex autoimmune disorders, IP through 2047.
• ↑Reached 52-week high at $114.60 with average target of $124.27.
• ↓Q2 2026 net loss of $50.22M with zero revenue, cash burn ongoing.